Neurotrack is transforming the diagnosis of Alzheimer’s disease. Through a safe and non-invasive test, its technology can predict the risk of developing mild cognitive impairment and Alzheimer’s disease years before symptoms occur. Conceived at Emory University and validated by a 5-year study funded by the National Institutes of Health (NIH), it will give pharmaceutical companies better tools to recruit patients for clinical trials, leading to the development of life-saving drugs.
Neurotrack is backed by Founders Fund and Social + Capital, and was the winner of more than $7M in grants from the NIH. It was named Best Health Company at SXSW, DEMO, and participated in the Rock Health accelerator.
Latest funding size
Time since last funding
|about 1 year|
|Founders Fund, Khosla Ventures, AME Cloud Ventures, Social Capital, iSeed Ventures|